-
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Share
- Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
- Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”
Contacts
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86
Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell
More News From Medincell
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simultaneously in Engli...
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simult...
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: Jefferies Annual NY Biotech Conference Dates: June 2-4, 2026 Location: New-York Presentation: 9:55 AM ET Jun...
